

TPE DEC . 0 1 2004 SAT & TRA

1/22









 $\begin{array}{rcl} \mbox{Chloroquine} & - & 4 & \mu \mbox{M} \\ \mbox{Chloroquine} & - & 40 & \mu \mbox{M} \\ \mbox{Chloroquine} & - & 400 & \mu \mbox{M} \end{array}$


EICOSAPENTAENOIC ACID – 1 μ M EICOSAPENTAENOIC ACID – 10 μ M EICOSAPENTAENOIC ACID – 100 μ M

 $\begin{array}{rcl} \mbox{CAMPTOTHECIN} & - & 1 \ \mu \mbox{M} \\ \mbox{CAMPTOTHECIN} & - & 10 \ \mu \mbox{M} \\ \mbox{CAMPTOTHECIN} & - & 100 \ \mu \mbox{M} \end{array}$

DOXORUBICIN - 0.1 μ M DOXORUBICIN - 1 μ M DOXORUBICIN - 10 μ M

MG-132 - 40 μ M FLAG-LUC 100 PPC VEHICLE

3/22



.


X


•


4/22

Fig. 1D


			DOXIL	– 0.4µg/ml – 4µg/ml – 40µg/ml
			CISPL/	ATIN 0.2μg/ml ATIN 2μg/ml ATIN 20μg/ml
			TAXOL	– 1.2μg/ml – 12μg/ml – 120μg/ml
			TANNIC	C ACID - 2 μM C ACID - 20 μM
			SIMVAS	C ACID – 200 μM STATIN – 2 μM STATIN – 20 μM
			SIMVAS	statin — 200 μm Tatin — 2 μm
			LOVAS	TATIN — 20 μΜ TATIN — 200 μΜ 32 — 40 μΜ
			FLAG-	LUC 100 PPC
1.00E+6	1.00E+5 1.00E+4 1.00E+4	1.00E+3 <u></u>		
LUCIFEF	RASE ACTIVITY	(RLU/mg)		







.







Fig.4




10/22



,

Fig.5B





٠

Fig.5D

LLnL 40 μ M



Fig.5C

LLnL 40µM/DOX 5µM




Fig.5E




Fig.5F

TITLE: COMPOUNDS AND METHODS FOR PHARMICO-GENE THERAPY OF EPITHELIAL SODIUM CHANNEL ASSOCIATED DISORDERS INVENTOR NAME: John F. Engelhardt et al. SERIAL NO.: 10/815,557









Fig.6















15/22











•


.






c









r


.

19/22





..



1

;

!

•

21/22

SAMPLE	AVG RLU/mg	STDEV	FOLD CHANGE
VEHICLE	2.95E+03	9.01E+02	
AAV2 FLAG-LUCIFERASE	1.11E+05	3.77E+04	1.00
MG-132 - 20 μM	1.43E+06	1.72E+06	12.90
DOXORUBICIN 6 μ g/ML	2.10E+07	4.57E+06	189.36
DOXORUBICIN 3 μ g/ML	6.55E+06	1.15E+05	58.99
DOXORUBICIN 0.6 μ g/ML	2.55E+05	1.30E+05	2.30
· ·			
DAUNORUBICIN 6 μ g/ML	3.17E+08	1.41E+08	2855.65
DAUNORUBICIN 3 μ g/mL	2.40E+07	2.72E+06	216.42
DAUNORUBICIN 0.6 μ g/ML	4.09E+05	6.41E+04	3.69
ELLENCE 6 μ g/ML	1.06E+08	4.85E+07	952.50
ELLENCE 3 µg/ML	1.33E+07	2.70E+06	120.13
ELLENCE 0.6 μ g/ML	3.81E+05	1.78E+05	3.43
IDAMYCIN 6 µg/ML	3.87E+04	2.00E+04	0.35
IDAMYCIN 3 µg/ML	5.99E+08	1.91E+08	5396.31
IDAMYCIN 0.6 μ g/ML	5.30E+07	1.48E+07	477.76

•

Fig. 14B

I.

ξī.

1

ř

22/22

